Physician Perceptions of Estrogen Agonist/Antagonists in Menopausal Health:
A Survey to Address Osteoporosis, Urogenital Health and Breast Concerns in Menopause and Breast Cancer Survivorship

poster1

DOWNLOAD

 

Lasofoxifene 0.25 mg Compared with Raloxifene 60 mg for Effects on Bone Mineral Density and Markers of Bone Turnover: Results from the Phase 3 Comparison of Raloxifene and Lasofoxifene (CORAL) Trial

poster2

DOWNLOAD

 

Reported Sexual Activity and Orgasm Frequency in a Comparative Study
of the SERMs Lasofoxifene and Raloxifene in an Osteoporosis Prevention Study

poster2

DOWNLOAD

 

Lasofoxifene, an Estrogen Agonist/Antagonist, Improves Symptoms of Genitourinary Syndrome and Menopause (GSM) and Physiologic Markers Associated with Vulvovaginal Atrophy (VVA) in Two Large Phase 3 Studies

poster2

DOWNLOAD